EMA Authorised: Zabdeno (recombinant adenovirus type 26 (Ad26) encoding the glycoprotein (GP) of the Ebola virus Zaire (ZEBOV) Mayinga strain) — Janssen-Cilag International N.V.

View source ↗

Summary

The EMA authorised Zabdeno, a recombinant Ad26 Ebola vaccine by Janssen-Cilag International N.V., for prevention of Ebola virus disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Zabdeno (Ad26.ZEBOV vaccine)

Snippet

Status: Authorised. Therapeutic area: Hemorrhagic Fever, Ebola. MAH: Janssen-Cilag International N.V.. Decision date: 28/03/2025